Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.70%
#2 Ontology Gas Ontology Gas +17.76%
#3 GoPlus Security GoPlus Security +9.80%
#4 Janction Janction +9.64%
#5 DMT-NAT DMT-NAT +7.80%
#6 Provenance Blockchain Provenance Blockchain +6.63%
#7 B3 (Base) B3 (Base) +6.09%
#8 Ontology Ontology +6.08%
#9 Status Status +5.87%
#10 Everything Everything +5.64%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Curanex Pharmaceuticals Inc Common Stock Curanex Pharmaceuticals Inc Common Stock

Curanex Pharmaceuticals Inc Common Stock

CURX
Classificação em ações #34062
Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused... Curanex Pharmaceuticals Inc. is an emerging biopharmaceutical company focused on identifying, advancing, and bringing to market plant-based medicines to address various inflammatory conditions. Their primary drug candidate, Phyto-N, is currently in development for a broad spectrum of health issues, including but not limited to ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, gout, and acne. Established in 1996 and based in Jericho, New York, the company was formerly known as Fordman Pharma Inc. before adopting its current name in November 2023.
Preço da ação
$0.223
Última sincronização: 2026-08-14
Valor de mercado
$6.32M
Variação (1 dia)
1.64%
Variação (1 ano)
-
País
US
Negociar Curanex Pharmaceuticals Inc Common Stock (CURX)

Categoria

Healthcare
Lucros da Curanex Pharmaceuticals Inc Common Stock (CURX)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Curanex Pharmaceuticals Inc Common Stock, os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Curanex Pharmaceuticals Inc Common Stock de 2026 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
Não há dados suficientes para as datas fornecidas.
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE